Nonsteroidal anti-inflammatory drugs (NSAIDs) relieve pain, inflammation, and fever by inhibiting cyclooxygenases (COXs). Nonsteroidal anti-inflammatory drugs selective for COX-2 were developed to inhibit the major enzymatic source of the prostaglandins that mediate pain and inflammation while sparing COX-1-derived prostaglandins that contribute dominantly to gastric cytoprotection. Indeed, such purpose-designed COX-2 inhibitors reduced the incidence of serious gastrointestinal adverse effects when compared with traditional NSAIDs; however, they confer a small but absolute cardiovascular hazard. The hazard might also extend to traditional NSAIDs, which are relatively selective for COX-2, such as diclofenac, meloxicam, and etodolac. The occurrence of complications and the therapeutic responses to individual NSAIDs may vary substantially from patient to patient. Exploitation of detectable variability in the biochemical response to NSAIDs may offer an approach to the personalization of the management of risk and benefit.
GrosserT, FriesS, FitzGeraldGA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4–15.
2.
DayRO, GrahamGG, WilliamsKM, . Variability in response to NSAIDs. Fact or fiction?Drugs. 1988;36(6):643–651.
3.
FriesS, GrosserT, PriceTS, . Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology. 2006;130(1):55–64.
4.
GorreME, MohammedM, EllwoodK, . Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876–880.
5.
BernsK, HorlingsHM, HennessyBT, . A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395–402.
6.
SchwarzUI, RitchieMD, BradfordY, . Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358(10):999–1008.
7.
BombardierC, LaineL, ReicinA, . Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med. 2000;343(21):1520–1528, 1522 p following 1528.
8.
OttE, NussmeierNA, DukePC, . Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003;125(6):1481–1492.
9.
NussmeierNA, WheltonAA, BrownMT, . Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081–1091.
10.
SchnitzerTJ, BurmesterGR, MyslerE, . Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364(9435):665–674.
11.
CannonCP, CurtisSP, FitzGeraldGA, . Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(>9549):1771–1781.
12.
GrosserT, YusuffS, CheskisE, . Developmental expression of functional cyclooxygenases in zebrafish. Proc Natl Acad Sci U S A. 2002;99(12):8418–8423.
13.
SmythEM, GrosserT, WangM, . Prostanoids in health and disease. J Lipid Res. 2009;50Suppl:S423–S428.
14.
NarumiyaS, FitzGeraldGA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest. 2001;108(1):25–30.
15.
GaravitoRM, DeWittDL. The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim Biophys Acta. 1999;1441(2-3):278–287.
16.
PicotD, LollPJ, GaravitoRM. The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 1994;367(6460):243–249.
17.
BresalierRS, SandlerRS, QuanH, . Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092–1102.
18.
ZimmermannKC, SarbiaM, SchrorK, . Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol. 1998;54(3):536–540.
19.
MizunoH, SakamotoC, MatsudaK, . Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 1997;112(2):387–397.
20.
ShigetaJ, TakahashiS, OkabeS. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J Pharmacol Exp Ther. 1998;286(3):1383–1390.
21.
LipskyPE, BrooksP, CroffordLJ, . Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med. 2000;160(7):913–920.
22.
SilversteinFE, FaichG, GoldsteinJL, . Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247–1255.
23.
SinghG, FortJG, GoldsteinJL, . Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med. 2006;119(3):255–266.
24.
WitterJ. Celebrex Capsules (Celecoxib). NDA 20-998/S-009. Medical Officer Review. Silver Spring, MD:US Department of Health and Human Services Food and Drug Administration; 2000.
25.
FriesJF, MurtaghKN, BennettM, . The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. 2004;50(8):2433–2440.
26.
ArehartE, StithamJ, AsselbergsFW, . Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res. 2008;102(8):986–993.
27.
ChengY, AustinSC, RoccaB, . Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296(5567):539–541.
28.
ChengY, WangM, YuY, . Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest. 2006;116(5):1391–1399.
29.
KobayashiT, TaharaY, MatsumotoM, . Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest. 2004;114(6):784–794.
MurataT, UshikubiF, MatsuokaT, . Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 1997;388(6643):678–682.
32.
SolomonDH, GlynnRJ, RothmanKJ, . Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008;59(8):1097–1104.
33.
PiniB, GrosserT, LawsonJA, . Prostaglandin E synthases in zebrafish. Arterioscler Thromb Vasc Biol. 2005;25(2):315–320.
34.
WangM, ZukasAM, HuiY, . Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A. 2006;103(39):14507–14512.
PatronoC, Garcia RodriguezLA, LandolfiR, . Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373–2383.
37.
BoutaudO, AronoffDM, RichardsonJH, . Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases. Proc Natl Acad Sci U S A. 2002;99(10):7130–7135.
DayRO, McLachlanAJ, GrahamGG, . Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet. 1999;36(3):191–210.
40.
PatrignaniP. Lumiracoxib: a viewpoint by Paola Patrignani. Drugs. 2004;64(19):2247–2248.
41.
ScottG, RordorfC, ReynoldsC, . Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet. 2004;43(7):467–478.
42.
HinzB, RennerB, ChereminaO, . Lumiracoxib inhibits cyclo-oxygenase 2 completely at the 50 mg dose: is liver toxicity avoidable by adequate dosing?Ann Rheum Dis. 2009;68(2):289–291.
43.
GrosserT. The pharmacology of selective inhibition of COX-2. Thromb Haemost. 2006;96(4):393–400.
44.
PatrignaniP, PanaraMR, GrecoA, . Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271(3):1705–1712.
45.
FitzGeraldGA, PatronoC. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345(6):433–442.
46.
WarnerTD, GiulianoF, VojnovicI, . Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96(13):7563–7568.
47.
GarciaRodriguez LA, Gonzàlez-PérezA.Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC. 2005;3:17.
48.
SchwartzJI, DallobAL, LarsonPJ, . Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol. 2008;48(6):745–754.
49.
ReillyIA, FitzGeraldGA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69(1):180–186.
50.
AwTJ, HaasSJ, LiewD, . Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005;165(5):490–496.
51.
BurleighME, BabaevVR, OatesJA, . Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105(15):1816–1823.
52.
EganKM, WangM, LucittMB, . Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation. 2005;111(3):334–342.
53.
CaponeML, SciulliMG, TacconelliS, . Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45(8):1295–1301.
54.
WilcoxCM, AllisonJ, BenzulyK, . Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol. 2006;4(9):1082–1089.
55.
ArboleyaLR, de la FigueraE, Soledad GarciaM, . Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study. Curr Med Res Opin. 2003;19(4):288–297.
56.
ZhaoSZ, WentworthC, BurkeTA, . Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf. 2004;13(5):277–287.
57.
MarkiewiczA, SemenowiczK. Time dependent changes in the pharmacokinetics of aspirin. Int J Clin Pharmacol Biopharm. 1979;17(10):409–411.
58.
LabrecqueG, DoreF, BelangerPM. Circadian variation of carrageenan-paw edema in the rat. Life Sci. 1981;28(12):1337–1343.
59.
RudicRD, McNamaraP, ReillyD, . Bioinformatic analysis of circadian gene oscillation in mouse aorta. Circulation. 2005;112(17):2716–2724.
60.
FDA. New Drug Application 20-998. Clinical Pharmacology and Biopharmaceutics Review Celecoxib. Bethesda, MD: Food and Drug Administration; 1998.
61.
TangC, ShouM, MeiQ, . Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000;293(2):453–459.
62.
WangM, SongWL, ChengY, . Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease. J Intern Med. 2008;263(5):500–505.
